Alternatives to Germany – Pharmaceutical products – Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Abs.8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sog. Zulassungsmodell 2025-08

Germany – Pharmaceutical products – 61. Generika-Ausschreibung

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach §130a Abs.8 SGB V zu verschiedenen Wirkstoff-/en/-kombinationen mit jederzeitiger Abschlussmöglichkeit im Rahmen des sog. Open House-Verfahrens

Germany – Pharmaceutical products – Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Vilanterol und Umeclidiniumbromid (ATC: R03AL03)

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Irbesartan und Hydrochlorothiazid (ATC: C09DA24)

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Entecavir (ATC: J05AF10 - in der Darreichungsform Filmtabletten)

Expected Outcome: Project results are expected to contribute to all the following expected outcomes: Advance in the achievement of the Strategic Energy Technology (SET) Plan’s research and innovation priorities and targets for wind energy; Efficient and effective support to wind energy research and innovation through alignment and cooperation among different actors, avoiding fragmentation of efforts; Energy producers and consumers benefit from increased performance of wind energy technologies with the focus on efficiency and flexibility, reduced cost, improved reliability and sustainability, operation and maintenance, safety, robustness and security during all stages of the lifetime of a wind energy farm from installation, operation and maintenance to decommissioning; Increased contribution of wind energy to the energy system, with minimal impacts on health and the environment (notably biodiversity and pollution) and at the lowest possible cost. Scope: The action contributes to address the Strategic Energy Technology (SET) Plan’s research and innovation priorities and targets for wind energy, as defined by the Implementation Working Group (IWG) on wind energy, the European…

Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes: Researchers of different disciplines use advanced multiscale Virtual Human Twins (VHTs) to expand the knowledge and understanding of cancer onset and progression Healthcare professionals and researchers have access to advanced VHT-based solutions that model cancer onset and progression over time, contributing to improve personalised treatments Researchers, healthcare professionals, innovators and citizens have access to cancer VHTs through the UNCAN.eu and the advanced Virtual Human Twin platforms Scope: Virtual human twins (VHTs) are digital representations and in-silico models of an individual’s health and disease at different levels of the human anatomy (e.g. cells, tissues, organs or organ systems) for the prevention, prediction, screening, diagnosis and treatment of a disease, as well as the selection and personalisation of intervention options [1] . The proposed topic will contribute to the EU Cancer Mission objectives by improving the accuracy of dynamic and multiscale VHTs to better understand cancer…

Expected Outcome: Activities under this topic will support the EU Vision for Agriculture and Food , the EU Soil Strategy for 2030 , including the implementation of the EU Soil Monitoring and Resilience Directive, the EU Adaptation Strategy, the EU Water Resilience Strategy, and the forthcoming European Climate Adaptation Plan. Project results are expected to contribute to all the following expected outcomes: enhanced monitoring of soils at subnational level (e.g. regions and municipalities) leading to an overall improved soil resilience against extreme weather events, particularly in terms of soils’ capacity to withstand and recover from floods, droughts, heatwaves and broader temperature fluctuations; tailored soil management practices and solutions that improve soil health are adopted, promoting sustainable land management, enhancing food system resilience, including food security [1] , and strengthening the overall resilience of agricultural systems to current and future climate extreme events. Scope: Developing and scaling practical solutions to enhance soils’ resilience to extreme weather events is crucial for climate change adaptation. As extreme weather events like…

Expected Outcome: Proposals submitted to this call are expected to address several of the following elements: • Scaling of wafer-level photonic processes for key materials (e.g. SiN, InP, GaAs),including process integration, yield optimisation, and manufacturability at highvolumes. • Development of packaging and test solutions that are scalable, automated, andcompatible with co-packaged optics and advanced photonic-electronic integration. • Integration of heterogeneous materials and components, such as on-chip lasers,modulators, and detectors, using advanced packaging and assembly approaches. • Design-process-equipment co-optimisation, enabling repeatable, cost-effectiveproduction of complex photonic circuits and systems, including use of PDKs andvalidated building blocks. • Demonstration of system-level functionality through application-relevant use casesin strategic sectors (e.g. AI, sensing, telecommunication, mobility, health, defence),with quantified performance metrics and clear market relevance.

Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes: Healthy people and in particular people at risk will benefit from microbiome tests and programmes that can discover and predict their transition to cancer before the onset of disease. People will have a better understanding of risks and will be enabled to address risks early by following treatments or adapting their lifestyles, including nutrition and other interventions. Physicians will be able to start cancer treatments earlier with a higher success rate. Policy makers and authorities will be enabled to develop and implement advanced and strategic programmes addressing cancer prevention. Scope: This topic will contribute to the achievement of the EU Cancer Mission’s objective to achieve better cancer prevention and early detection. The focus is on the development of validated microbiome tools, an assessment of predispositions, the comparison with other predictive tools and risk modelling approaches. Cancer often develops over several years and progresses silently before symptoms appear. Some cancers are…

Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes: Patients with refractory cancers and their caregivers/families will have access to optimised, tailored and affordable immunotherapeutic interventions that increase their quality of life, across European regions, EU Member States and Associated Countries; Healthcare professionals and academia will have access to clinical evidence, on effectiveness of immunotherapeutic interventions, to deploy evidence-based treatment interventions with improved patient selection that improve outcomes in real life, i.e. in routine healthcare, for patients with refractory cancers who often present with co-morbidities; National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries will have the evidence to implement and reimburse optimised and affordable immunotherapeutic interventions in their healthcare systems, including in everyday medical practice. Scope: While cancer research and innovation have generated novel treatment options, patients with refractory cancers…